Latest Financial Stability News

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Aeris Environmental Ltd reported a modest revenue increase for FY2025 but saw its operating loss widen sharply to $4.12 billion, raising concerns about its financial stability.

Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.

Duxton Water Limited reported a remarkable 197% increase in net profit after tax for the half-year ending June 2025, alongside a fully franked dividend and a rise in net asset value per share.

MPower Group Limited has announced a binding agreement to sell its main renewable energy assets for approximately $19 million, reporting a net loss of $4.1 million for FY2025 largely due to discontinued operations.

Investor Centre Limited delays its 2025 Annual Report following the liquidation of key funder Amram Corp, triggering a likely trading suspension.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

The Star Entertainment Group reported a $471.5 million net loss for FY25, marking a 72% improvement from the prior year but underscored by ongoing regulatory challenges and a complex joint venture exit.

AF Legal Group has reported a record-breaking FY25 with revenue up 27% to $27.6 million and a 77% jump in normalised profit before tax. The firm’s strategic acquisitions and operational improvements set a positive tone for FY26 growth.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.